CC
ARQT icon

Centiva Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Centiva Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$266K – 1780
2023
Q3 		$266K Hold
50,000
– – 0.01% 1239
2023
Q2 		$477K Buy
+50,000
New +$555K 0.01% 851

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Centiva Capital's ARQT Position: Q1 2024 in Review

Centiva Capital sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 20,984 shares — an estimated $67.8K sold.

Centiva Capital first reported a position in ARQT in Q1 2022 and held it in 6 quarters. The position peaked at $2.2M in Q1 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Centiva Capital reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Centiva Capital sold 20,984 Arcutis Biotherapeutics shares in Q1 2024, an estimated $67.8K.
  • Centiva Capital first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 6 quarters.
  • Centiva Capital's Arcutis Biotherapeutics position peaked at $2.2M in Q1 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Centiva Capital's 13F filing for Q1 2024, filed 15 May 2024.